A&O Shearman, formed from the merger of Allen & Overy and Shearman & Sterling, has reported $3.7 billion in revenue for its first fiscal year endin...
Stealth BioTherapeutics has resubmitted its application for elamipretide, a drug intended to treat Barth syndrome, after an initial rejection by th...